Similar articles

• Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.

  Soljanik I. Soljanik I. Eur Urol. 2010 Jan;57(1):153. doi: 10.1016/j.eururo.2009.04.047. Epub 2009 May 7. Eur Urol. 2010. PMID: 19446950 No abstract available.
• Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.

  Zát'ura F, Vsetica J, Abadías M, Pavlík I, Schraml P, Brod'ák M, Villoria J, Sust M; E-4018/CL50 Study Group. Zát'ura F, et al. Eur Urol. 2010 Jan;57(1):145-52. doi: 10.1016/j.eururo.2009.04.045. Epub 2009 May 7. Eur Urol. 2010. PMID: 19446951 Clinical Trial.
• Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.

  Martínez-García R, Abadías M, Arañó P, Perales L, Ruíz JL, Sust M, Conejero J; ESCLIN 006/00 study group. Martínez-García R, et al. Eur Urol. 2009 Jul;56(1):184-90. doi: 10.1016/j.eururo.2008.04.027. Epub 2008 Apr 18. Eur Urol. 2009. PMID: 18485575 Clinical Trial.
• Overactive bladder: an update.

  Hashim H, Abrams P. Hashim H, et al. Curr Opin Urol. 2007 Jul;17(4):231-6. doi: 10.1097/MOU.0b013e32819ed7f9. Curr Opin Urol. 2007. PMID: 17558264 Review.
• Fesoterodine for the treatment of overactive bladder.

  Tzefos M, Dolder C, Olin JL. Tzefos M, et al. Ann Pharmacother. 2009 Dec;43(12):1992-2000. doi: 10.1345/aph.1M308. Epub 2009 Nov 17. Ann Pharmacother. 2009. PMID: 19920160 Review.